New shot could cut bleeding in Tough-to-Treat hemophilia
NCT ID NCT06312475
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a weekly injection called KN057 to see if it can prevent bleeding episodes in people with hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). About 53 male participants aged 12 to 70 will be randomly assigned to receive KN057 or no preventive treatment for 26 weeks, then everyone gets KN057 for another 26 weeks. The goal is to measure how many bleeding episodes occur and whether the drug is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KN057 (a drug injected under the skin once a week)
- What this could lead to
- If it works, this could provide a new option to prevent bleeding episodes in people with hemophilia who have developed inhibitors, reducing the need for on-demand treatment.
- What could go wrong
- This is a small Phase 3 trial with only 53 participants, so results may not apply to everyone. The drug is still experimental, and its long-term safety and effectiveness are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A WITH INHIBITOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.